Leemore Dafny is the Bruce V. Rauner Professor of Business Administration at the Harvard Business School. Dr. Dafny also serves on the faculties of the John F. Kennedy School of Government and the interdisciplinary Program in Health Policy.
Professor Dafny’s research examines interactions among payers and providers of health care services, and competitive conduct in pharmaceutical markets. Much of her work focuses on the intersection of industry and public policy, particularly antitrust enforcement. Dafny has published in academic journals such as The American Economic Review and The New England Journal of Medicine, and her findings have been featured in popular media such as the New York Times and The Wall Street Journal.
Professor Dafny graduated from Harvard College and worked as a consultant with McKinsey & Company prior to earning her PhD in economics from the Massachusetts Institute of Technology. She is a research associate of the National Bureau of Economic Research, on the editorial board of several academic journals, and a board member of the American Society of Health Economists and the Health Care Cost Institute. She co-directs the Harvard Business School PhD Program in Business Economics.
Professor Dafny’s expertise spans both the public and private sectors. She currently serves on the Panel of Health Advisers for the Congressional Budget Office. In 2012–2013, she was Deputy Director for health care and antitrust in the Bureau of Economics at the Federal Trade Commission. She also advises companies, government agencies, and nonprofits on a variety of issues including antitrust matters, strategic decisions, and public policy.
Involving the private sector in Chinese health care could be beneficial, but a market only works with the right ingredients. An American health care economist shares lessons the U.S. has learned about its downsides.
Insights Report by Leemore Dafny & Chris DeRienzo
Efforts to mitigate rising health care costs have left most industry participants — patients, providers, and payers alike — frustrated at the lack of progress. While there is plenty of blame to go around, a significant open question remains: how responsible are patients for reducing costs?
Three components for treating the unhealthy, uncompetitive U.S. health care market — beginning with a buyer’s revolt.
Clip by Leemore Dafny, David Lansky, Robert Galvin & Lynn Garbee
The companies most capable of leading transformation in health care coverage are the ones that least need to.
Clip by David Lansky, Robert Galvin, Lynn Garbee & Leemore Dafny
Why are employers hesitating? What do they value and want to invest in when it comes to health care payment plans?
Interview by Robert Galvin & Leemore Dafny
Will Amazon–Berkshire Hathaway–JP Morgan and CVS-Aetna change the health care game? To one health care employer purchaser, these announcements feel a lot like Groundhog Day.
What might one of the largest mergers in history mean for the health care delivery system?
Health care stakeholders are not aligned in important goals and in large part are not working together to achieve value-based care, according to the NEJM Catalyst Insights Council. They are waiting on government regulators to change the payment model — including, possibly, single-payer health care.
“What we aim to do is to create something akin to a public utility that is going to put public good first.”